PRECLINICAL REPORTSPreclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenograftsNémati, Faribaa; Bras-Gonçalves, Ruig; Fontaine, Jean-Jacquesh; de Pinieux, Gonzaguei; De Cremoux, Patriciab; Chapelier, Alainj; Daniel, Catherinec; Laurent-Puig, Pierref; Livartowski, Alainc; Judde, Jean-Gabrielk; Bordier, Vincente; Poupon, Marie-Francea; Decaudin, Didiera dAuthor Information Preclinical Investigation Laboratory, Departments of aTranslational Research bTumor Biology cClinical Oncology dClinical Hematology eAnimal Experiments Unit, Research Section, Institut Curie fInserm U775, Hôpital Européen Georges Pompidou, Paris gInstitut de Recherche en Cancérologie de Montpellier, Parc Euromédecine, Montpellier hDepartment of Pathology, Alfort Veterinary School, Maisons-Alfort iDepartment of Pathology, Hôpital Trousseau, Tours jDepartment of Chest Surgery, Hôpital Foch, Suresnes kXenTech, Evry, France Correspondence to Dr Didier Decaudin, MD, PhD, Laboratoire d'Investigation Pré-clinique/Service d'Hématologie Clinique, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, France Tel: +33 1 44 32 46 90; fax: +33 1 53 10 40 11; e-mail: [email protected] Received 29 April 2009 Revised form accepted 24 June 2009 Anti-Cancer Drugs: November 2009 - Volume 20 - Issue 10 - p 932-940 doi: 10.1097/CAD.0b013e32833009cc Buy Metrics Abstract The success of treatment of advanced non-small-cell lung cancer (NSCLC) remains very poor. The aim of this study was, on a series of NSCLC xenografts, to compare the efficacy of standard cisplatin-based or docetaxel-based chemotherapy. Seven human xenografts were obtained from six patients (two xenografts were derived from primary or metastatic tumors of the same patient). Three xenografts were adenocarcinomas and four were squamous cell carcinomas. All xenografts reproduced the same histology as that of the patient's original tumor. Docetaxel, administered as single-agent chemotherapy, induced a significant response in five of the seven NSCLC xenografts (71%), without significant increase after combination with cisplatin, vinorelbine, or gemcitabine. Relative expression of genes putatively involved in drug response was also studied in all xenografts and did not explain the variability of drug sensitivity. In conclusion, this panel of human NSCLC xenografts reliably reproduces the data obtained in patient tumors and the relative sensitivity to docetaxel reported in NSCLC patients. © 2009 Lippincott Williams & Wilkins, Inc.